References
- International Atomic Energy Agency - Coordinated Research Projects. Available from: http://www.iaea.org/monaco/page.php?page =2117. (last accessed October 2016).
- Carr R, Fanti S, Paez D, et al. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1936–1944.
- Cheson BD, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
- Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–1073.
- Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828–1837.
- Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111:5509–5514.
- Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone in patients with newly diagnosed diffuse large B-cell lymphoma: a phase 3 comparison of intensification with 14-day versus 21-day cycles. Lancet. 2013;38:1817–1826.
- Cavalli F. An appeal to world leaders: stop cancer now. Lancet. 2013;381:425–426.
- Naresh KN, Advani S, Adde M, et al. Report of an international network of cancer treatment and research workshop on non-Hodgkin lymphoma in developing countries. Blood Cells Mol Dis. 2004;33:330–337.
- Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Invest. 2008;26:306–316.
- Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972–978.
- Morales D, Beltran B, de Mendoza F, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51:66–72.
- Okamoto A, Yanada M, Inaguma Y, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. Hematol Oncol. 2015. [Epub ahead of print]. doi: 10.1002/hon.2245.
- Hogfeldt T, Bahnassy AA, Kwiecinska A, et al. Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious areas have different inflammatory gene signatures. Leuk Lymphoma. 2013;54:996–1003.
- Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predict prognosis in patients with diffuse large B-ccell lymphoma treated with immunochemotherapy. Blood. 2011;117:4836–4843.
- Reber R, Banz Y, Garamvolgyi E, et al. Determination of the molecular subtypes of diffuse large B-cell lymphoma using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. Swiss Med Wkly. 2013;143:w13748. Doi: 10.4414/smw.2013.13748.